Actuate Therapeutics
ACTU
19 hedge funds and large institutions have $80.5M invested in Actuate Therapeutics in 2024 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
2,728% more capital invested
Capital invested by funds: $2.85M → $80.5M (+$77.7M)
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
90% more funds holding
Funds holding: 10 → 19 (+9)
49.84% more ownership
Funds ownership: 1.96% → 51.8% (+50%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Voss Capital
Houston,
Texas
|
+$451K |
| 2 |
Mercer Global Advisors
Denver,
Colorado
|
+$133K |
| 3 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$131K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$117K |
| 5 |
Goldman Sachs
New York
|
+$91.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$1.04M |
| 2 |
LCAM
Long Corridor Asset Management
Hong Kong
|
-$931K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$286K |
| 4 |
Citigroup
New York
|
-$89.5K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$25.3K |
ACTU Hedge Fund Activity: Q4 2024 in Review
19 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Actuate Therapeutics (ACTU) for Q4 2024, worth a combined $80.5M — up 2,728% from $2.85M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ACTU positions and 4 closed out — a net gain of 9 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Voss Capital, opening a new position worth an estimated $451K. The largest seller was AWM Investment Company, exiting entirely with an estimated $1.04M sold.
- 19 institutional investors held Actuate Therapeutics (ACTU) as of Q4 2024, up from 10 in Q3 2024.
- Funds reported $80.5M of Actuate Therapeutics stock for Q4 2024, up 2,728% quarter-over-quarter.
- 13 funds opened new Actuate Therapeutics positions in Q4 2024 and 4 closed out, a net change of +9 holders.
- The largest Actuate Therapeutics buyer in Q4 2024 was Voss Capital, an estimated $451K added.
- The largest Actuate Therapeutics seller in Q4 2024 was AWM Investment Company, an estimated $1.04M sold.
Based on aggregated 13F filings for Q4 2024.